Hikma Pharma signs agreement with Civica Rx to produce 14 sterile injectable medications

Under the agreement, Hikma will produce 14 essential sterile injectable medications for Civica as a private label distributor, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's labelling and National Drug Code (NDC).

LONDON: Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company and Civica Rx (Civica, Inc.) recently announced a five-year agreement to manufacture and supply Civica's growing membership of US health systems with medications that are often in short supply in US hospitals.

Under the agreement, Hikma will produce 14 essential sterile injectable medications for Civica as a private label distributor, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's labelling and National Drug Code (NDC).

These medicines are used daily by hospitals in emergency care, surgery, pain management and treating hypertension. The list of products included in the agreement will be publicly announced in the near future, and initial shipments are expected to begin before the end of 2019.

Commenting on the partnership, Daniel Motto, Hikma's EVP of Commercial & Business Development, US Injectables said, "Hikma is thrilled to be partnering with Civica to reduce drug shortages, and we share their commitment to providing hospitals and doctors with a steady and reliable supply of high-quality injectable medicines needed for successful patient care."

"This agreement recognizes both our ability to deliver a large and consistent supply of quality medicines and the significant investments we have made to expand our injectable manufacturing capacity and capabilities, " Daniel added.

Martin VanTrieste, President and CEO of Civica Rx said, "We applaud Hikma's clear commitment to reducing drug shortages."

"Our partnership will help us make an impact as quickly as possible. We specifically chose Hikma because of their strong manufacturing capabilities and believe their excellent quality and supply record will be key to our success in ensuring vital medications are consistently available for hospitals and patients who need them, " Vantrieste added.

"We are privileged to be working with Civica and we appreciate their five-year commitment to guaranteed demand and fair and sustainable pricing, which supports more effective production planning and long-term investments in manufacturing," said Riad Mishlawi, President, Hikma Injectables.

"We believe Hikma's size and scale, broad portfolio of medicines and robust pipeline across growing therapeutic areas will enable us to build on this partnership in the future. We are committed to working with Civica and all of our customers as a reliable partner, capable of serving the growing needs of US hospitals and clinics for a wide range of essential medicines, " Riad added.

Read Also: Hikma Pharma backs annual outlook boosted by medicine demand